Table 2.

Anti-CD40L drugs, target, mechanism of action, and important features

Target	Drug	MOA	Notes
CD40	CFZ533	The modified Fc domain of the human antagonist anti-CD40 monoclonal IgG1 antibody enables it to mediate Fc Gamma-dependent effector function	Promotes allograft survival following kidney transplant
	Bleselumab [ASKP1240]	It is an IgG4 antibody (humanized monoclonal antibody) that causes suppression of both cellular and humoral immune systems	This drug has safety against psoriasis and it does not cause side effects like infusion reactions, cytokine release syndrome and any thromboembolic events like atherosclerosis or pulmonary embolism. It also prevents rejection of renal and hepatic transplants
	BI-655064	It is a humanized antagonist IgG1 mAB. It mechanism of action is to prevent Fc-mediated effector function including cytotoxicity and platelet activation